Despite uncertainty, New York seeds expansive hemp program

Legality of CBD remains the subject of HIA lawsuit

New York Governor Andrew Cuomo hopes to woo hemp startups to the “Hempire State,” committing $10 million in startup capital through various funds administered by Empire State Development.

Citing more than 25,000 products that can be manufactured using industrial hemp, including clothing, food, building materials and pharmaceuticals, Empire State Development announced that $5 million has been allocated for grants to support research and production, and $5 million will be available to fund capital costs related to processing, including for construction and equipment. Grants awarded for processing may provide a minimum of $10,000 and a maximum of $500,000 for up to 50% of the total project costs; the recipient must match the remaining 50%.

The state’s capitalistic approach toward industrial hemp bears no resemblance to the state’s stance on medical cannabis. New York’s medical cannabis program is among the most restrictive in the country and is frequently criticized for its lack of patient access, whole-plant applications and affordable medication, even after the state added both post-traumatic stress disorder and chronic pain as qualifying conditions.

Hopeful that New Yorkers will embrace industrial hemp, Cuomo has announced several initiatives targeted at expanding the sector, including lifting the cap on authorized growing sites and hosting an industrial hemp summit to explore opportunities in the hemp industry.

Prior to the $10 million capital infusion, only 21 businesses had been licensed to grow industrial hemp. According to the Department of Agriculture, as of the state-imposed deadline of Nov. 22, 2017, New York received 103 applications from farms and businesses interested in growing industrial hemp in 2018.

Unlike growers, applications for hemp processors are being accepted on a rolling basis. Applications involving the processing of industrial hemp into products for ingestion, inhalation or topical uses are to be reviewed by the state Department of Health and other agencies.

The Department of Agriculture completed its initial review of all industrial hemp grower applications and, by mid-February, had received all responses from the Department of Health on applications that had been sent for review.

However, at that time, the Department of Health was still drafting a research partnership agreement with the Department of Agriculture, anticipating that applications specific to the production of CBD-rich industrial hemp or hemp products will require a separate rider.

New York’s extensive financial commitment to the hemp industry is the first of its kind, yet it arrives at a time when the federal legality of manufacturing products containing CBD remains in legal limbo.

Under the Agricultural Act of 2014 (the Farm Bill), Congress exempted “industrial hemp” from the definition of “marihuana” under the Controlled Substances Act, provided the crop naturally contains less than a “trace” amount of THC (0.3%) on a dry weight basis and is legally grown in states with enacted legislation under the Farm Bill (or certain countries abroad).

The Industrial Hemp Amendment to the Consolidated Appropriations Act of 2016 (the spending rider) removes funding that prohibits transportation, processing, sale or use of industrial hemp grown in accordance with the Farm Bill.

Read together, the production/cultivation and transportation of industrial hemp — in interstate commerce — is federally legal.

The legality of products derived from industrial hemp is less clear. In December 2016, the DEA published a “final rule,” the “Establishment of a New Drug Code for Marijuana Extract,” that classifies any cannabis extract, including CBD, regardless of its source, as a Schedule I drug. This rule conflicts with the Farm Bill and the spending rider and is currently the subject of litigation between the Hemp Industries Association and the DEA.

In January, 28 members of Congress (22 Democrats and six Republicans) filed an amicus brief in support of the HIA, admonishing the DEA’s inclusion of “extracts” from Farm Bill-compliant hemp in its 2016 definition of “marihuana extract.”

In their brief, members of Congress argue, among other things, that by the Farm Bill and the spending rider, Congress established rules for the executive branch and the individual states to respect in order to “research the viability of industrial hemp as an agricultural crop.” They ask the court to adhere to Congress’ actions and purposes and hold that the final rule constitutes an abuse of DEA authority.

Having bet $5 million on the future of hemp processing, the state of New York — among others — will certainly be watching the results.

Lauren Rudick represents investors and startup organizations in all aspects of business and intellectual property law, specializing in cannabis, media and technology. Her law firm, Hiller, PC (www.hillerpc.com), is a white-shoe boutique firm with a track record for success and handling sophisticated legal matters that include business and corporate law.

Comment

One response to “Despite uncertainty, New York seeds expansive hemp program”

  1. Lawrence Goodwin says:

    Thank you so much for another splendid article, Lauren. I admire all of your work. You offer the most delicious food for thought. 🙂

    Toward the end you delve into a development that is fraught with complications, one that seems only to have further divided America’s cannabis community. As if a full 81 years of fraudulent “marihuana” law were not enough, in 2014 the U.S. Congress committed another egregious error by codifying the “0.3 percent” rule that prohibits the cannabinoid delta-9 tetrahydrocannabinol (THC) in Farm Bill-compliant crops. Most of today’s “hemp” advocates try to deflect attention from the fact that cannabidiol (CBD) is found primarily in the seedless, female flowers of cannabis plants—the same ones that Congress has labeled “marihuana” since 1937. CBD definitely is an “extract” of those flowers in the exact same manner as THC. I’m not defending the heartless Drug Enforcement Administration bureaucratic hacks. In a reportedly free country, they have no business dictating which cannabis compounds are “legal” are which are not—neither does Congress.

    The cannabis species, in the scientific terms of botany, are “dioecious.” They naturally develop male and female flowers on separate plants. When farmers grow both flower types together in a field, THAT is true cannabis “hemp,” from which they can reap the raw materials of fiber, pulp, leaves or seeds. The males act as pollinators. After pollination, females bear the seeds. There are NO two ways about this part of nature, folks, regardless of the 2014 Farm Bill language.

    Fortunately, we have legions of industrious and crafty cannabis growers in America who know the medical miracles that are possible when they separate the female flowers and grow them seedless (utilizing carefully isolated grow rooms and greenhouses; if the growers happen to prefer outdoor gardens, they may want to reconsider due to the spread of actual hemp farming and sharply higher amounts of male cannabis spores flying through the air). Packed inside these beautiful seedless, female flowers are the many dozens of microscopic cannabinoids, including CBD and THC. Earlier this year, a cannabis farmer from Vermont explained very clearly to me how CBD gets drastically reduced if there is any male pollination. That can only mean it is not derived from hemp crops, but from what the traitors in Congress still call “marihuana.”

The Marijuana Venture interview: Seattle Hempfest

When Washington voters legalized marijuana through Initiative 502 in 2012,…

Read More >

The Paper Trail

Matthew Glyer is not just running a printing a company.…

Read More >

Industry leaders to gather in San Diego to discuss future of indoor growing

As California policy makers develop codes for Controlled Environment Agriculture,…

Read More >
Website Design